Roche Diagnostics Hera Laboratory Planners
The specific committee of Genentech’s Board of Directors has authorized the agreement and recommends that Genentech shareholders tender their shares in Roche’s tender supply. Below the terms of the agreement, Affimed will receive $96 million in an initial upfront payment and other close to-term committed funding. Affimed might be eligible to obtain up to an added $5. billion over time, like payments upon achievement of specified development, regulatory and commercial milestones, and royalties on sales. The agreement is topic to customary closing situations, like clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and closing is anticipated to take place in the...